Xeris Biopharma Holdings (XERS) Goodwill & Intangibles (2021 - 2026)

Xeris Biopharma Holdings has reported Goodwill & Intangibles for 6 years, with the latest figure at $108.2 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles fell 9.11% year-over-year to $108.2 million; the trailing twelve-month figure through Mar 2026 stood at $108.2 million (down 9.11% YoY), and the FY2025 full-year result was $110.9 million, down 8.9% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $108.2 million, down from $110.9 million in the prior quarter.
• The five-year high for Goodwill & Intangibles was $151.6 million in Q1 2022, with the low at $108.2 million in Q1 2026.
• Historically, Goodwill & Intangibles has averaged $129.9 million across 5 years, with a median of $129.9 million in 2024.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles dropped 7.03% — and 2026, when it slipped 9.11%.
• Xeris Biopharma Holdings' Goodwill & Intangibles stood at $143.5 million in 2022, then decreased by 7.56% to $132.6 million in 2023, then declined by 8.18% to $121.8 million in 2024, then dropped by 8.9% to $110.9 million in 2025, then fell by 2.44% to $108.2 million in 2026.
• The last three Goodwill & Intangibles figures came in at $108.2 million (Q1 2026), $110.9 million (Q4 2025), and $113.6 million (Q3 2025), per Business Quant data.